Three SPAC IPOs on Deck to Price
by Kristi Marvin on 2018-11-13 at 3:05pm

Two SPACs are anticipated to price on Thursday, but there’s a chance we get all three.

It’s looks like we’re going to have a double header this week, since we’re hearing that Fintech III has moved their pricing to Thursday, alongside AMCI, which is already on the calendar for the same day. Plus, there’s the wildcard of Boxwood Merger Corp., which could make Thursday a hat-trick.

However, in light of the crowded schedule we thought it would be a good idea to summarize the terms for comparison:

Three SPAC IPOs

Besides the obvious difference in the amount of warrants included in AMCI’s unit and AMCI’s life (18 months), both Boxwood and Fintech III look pretty similar as far as structure.  This leaves us to focus on the other key differences –  sector focus, team and to a lesser extent, underwriter.  However, regarding underwriter, it’s not as important at IPO as it is at combination.  To be clear, the underwriter’s capital markets skills are still important upfront, but they are crucial on the back end when trying to steer a deal through the completion process.  However, all of the above three deals have underwriters with solid names and SPAC experience – it’s a bit of a level underwriting playing field.

Nonetheless, even just evaluating sector focus is difficult because as we’ve seen, a SPAC can really combine with a company in any sector.  Just look at Hunter Maritime, which was an extremely focused shipping team that wound up presenting a deal with a Chinese fintech company.  They don’t call it a “blind pool” for nothing.  So ultimately, we’re left to focus on team.

Looking at the teams of all three of these IPOs, the Fintech team is the one with two successful SPACs under their belt – Fintech I, which combined with CardConnect (and was ultimately bought by First Data for $15.00 per share), and Fintech II, which combined with International Money Express (IMXI) and closed yesterday at $12.50.  As we’ve said, over and over, experience in SPACs counts. That’s not to say that AMCI and Boxwood can’t bring just as good deals, but it’s a lot easier to make a bet on a team with a track record and knows how to navigate the always challenging “de-SPACing” process.

So, which one is going to have the most demand at IPO?  Only the book-runners really true know what their demand looks like (and frankly, if you them asked them, every single one will tell you demand is HUUUUGE, regardless of whether it is or not), but it’s hard to argue with betting on the Fintech III team.  Two previously successful deals gives them the edge.

Lastly, regarding AMCI, this SPAC recently amended its terms. They went from 1/2 warrant to a full warrant and 24 months life to 18 months.  Those are costly changes to the SPAC management team and were needed to sweeten the deal.  So, are these changes to the terms enough to get investors clamoring for this SPAC or is the change itself a sign of investor apathy?  Well, we’ll know soon enough, but my bets on Fintech III as the SPAC to most likely trade well above $10.00 day-one.

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved